Euclid Systems Corporation today announced the signing of a cooperation agreement with Wenzhou Medical University Eye Hospital.
"Thanks to a number of studies showing the ability of Euclid's Emerald™ brand Ortho-K lens to retard the progression (worsening) of myopia in children, the Chinese population are accepting this treatment in increasing numbers," stated Michael A Ross, MD, President and COO of Euclid. "This strategic partnership with the Wenzhou Medical University will further enhance Euclid's reputation as the leading provider of Ortho-K lenses in China and throughout Asia."
Through this cooperative agreement, Euclid will support and assist the University in several areas, including the training of new Optometrists and Ophthalmologists in the fitting and use of Orthokeratology lenses, as well as to study of the advantages of Orthokeratology for the prevention of the progression of myopia (nearsightedness) and for treatment for high myopes (extremely nearsighted) patients. Wenzhou University will support Euclid by presenting at Ophthalmology meetings and conferences, by being a resource for prescribing doctors throughout China, and by promoting the health benefits and care standards for Orthokeratology. Additionally the University will work with Euclid to open an Ortho-K Trial Center on the hospital grounds as a model for prescribing doctors in China.
Study reveals how brainstem neurons control eye movements